A gene therapy biotech is bursting onto the scene with 12 programs in tow. An ultra-rare neuro disease is up first

Nicole DeFeudis

Editor

In downtown Lowell, MA, tucked into one of the country’s oldest surviving textile mill complexes is a new biotech toiling away on next-gen CNS therapies …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

A gene therapy biotech is bursting onto the scene with 12 programs in tow. An ultra-rare neuro disease is up first

Nicole DeFeudis

Editor

Sign up to read this article for free.

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

A gene ther­a­py biotech is burst­ing on­to the scene with 12 pro­grams in tow. An ul­tra-rare neu­ro dis­ease is up first

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A gene therapy biotech is bursting onto the scene with 12 programs in tow. An ultra-rare neuro disease is up first

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings